title: Letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim--correction of a systematic review and meta-analysis of randomized controlled trials with G-CSF.
authors: Institute for Medical Statistics, Information and Epidemiology, Cologne University, Kerpener Str. 62, 50937, Cologne, Germany.
authors: W
authors: W
authors: Lehmacher
authors: GWD Consult Contract Research, Mozartstrasse 2-4, 63165, Muehlheim am Main, Germany. Manfred.Klasser@gwd-consult.de.
authors: M
authors: M
authors: Klasser
authors: TEVA GmbH, Charlottenstraße 59, 10117, Berlin, Germany.
authors: A
authors: A
authors: Duering
mesh_terms: D064147:Febrile Neutropenia / Q000517:prevention & control*; D005260:Female; D000069585:Filgrastim / Q000627:therapeutic use*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D011322:Primary Prevention
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim